DiaMedica Inc. Announces Results of Annual General and Special Meeting
December 20, 2013 17:50 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 20, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General...
DiaMedica Inc. Announces Filing of Final Prospectus
December 16, 2013 12:24 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 16, 2013) -
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
DiaMedica Inc....
DiaMedica Inc. Announces Public Offering
December 04, 2013 12:12 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 4, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announced today that it has filed a preliminary short form prospectus in connection with the...
DiaMedica to Present at the 25th Annual Piper Jaffray Healthcare
November 20, 2013 10:10 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Nov. 20, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, has been invited to present at the 25th Annual Piper...
DiaMedica Issues Stock Option Grant
November 11, 2013 17:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Nov. 11, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announces that the Board of Directors has granted options to purchase 100,000 common shares of...
DiaMedica's DM199 Named One of the Top Ten Cardiovascular/Metabolic Disease Projects to Watch
October 30, 2013 08:00 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Oct. 30, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company is pleased to announce Elsevier Business Intelligence has...
DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients
September 30, 2013 08:30 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Sept. 30, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company announced positive results from the second portion of the...
DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study
August 20, 2013 08:32 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - Aug. 20, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today announced that the final Type 2 diabetic patient has...
DiaMedica Issues Stock Option Grant
June 26, 2013 06:22 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - June 26, 2013) - DiaMedica Inc. (TSX VENTURE:DMA), announces that the Board of Directors has granted options to purchase 525,000 common shares of...
DiaMedica Advances DM-199 Phase I/II Clinical Program for Treatment of Type 2 Diabetes
June 24, 2013 08:30 ET
|
DiaMedica Inc.
MINNEAPOLIS, MINNESOTA--(Marketwired - June 24, 2013) - DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today provided an update on the ongoing clinical trial...